206 related articles for article (PubMed ID: 23192727)
21. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
22. NMR-based Drug Development and Improvement Against Malignant Melanoma - Implications for the MIA Protein Family.
Arnolds O; Zhong X; Tuo Yip K; Schöpel M; Kohl B; Pütz S; Abdel-Jalil R; Stoll R
Curr Med Chem; 2017; 24(17):1788-1796. PubMed ID: 28595551
[TBL] [Abstract][Full Text] [Related]
23. Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large.
Riechers A; Bosserhoff AK
Exp Dermatol; 2014 Jan; 23(1):12-4. PubMed ID: 24372647
[TBL] [Abstract][Full Text] [Related]
24. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
25. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
[TBL] [Abstract][Full Text] [Related]
26. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
27. Melanoma inhibitory activity promotes melanoma development through activation of YBX1.
Schmid R; Meyer K; Spang R; Schittek B; Bosserhoff AK
Pigment Cell Melanoma Res; 2013 Sep; 26(5):685-96. PubMed ID: 23672612
[TBL] [Abstract][Full Text] [Related]
28. p54nrb is a new regulator of progression of malignant melanoma.
Schiffner S; Zimara N; Schmid R; Bosserhoff AK
Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
[TBL] [Abstract][Full Text] [Related]
29. Repressing CD147 is a novel therapeutic strategy for malignant melanoma.
Hu X; Su J; Zhou Y; Xie X; Peng C; Yuan Z; Chen X
Oncotarget; 2017 Apr; 8(15):25806-25813. PubMed ID: 28445958
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes.
Tatzel J; Poser I; Schroeder J; Bosserhoff AK
Pigment Cell Res; 2005 Apr; 18(2):92-101. PubMed ID: 15760338
[TBL] [Abstract][Full Text] [Related]
31. Regulation of integrin activity by MIA.
Bauer R; Humphries M; Fässler R; Winklmeier A; Craig SE; Bosserhoff AK
J Biol Chem; 2006 Apr; 281(17):11669-77. PubMed ID: 16517605
[TBL] [Abstract][Full Text] [Related]
32. [MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma].
Bosserhoff AK; Golob M; Buettner R; Landthaler M; Hein R
Hautarzt; 1998 Oct; 49(10):762-9. PubMed ID: 9857251
[TBL] [Abstract][Full Text] [Related]
33. Functional role of MIA in melanocytes and early development of melanoma.
Poser I; Tatzel J; Kuphal S; Bosserhoff AK
Oncogene; 2004 Aug; 23(36):6115-24. PubMed ID: 15208686
[TBL] [Abstract][Full Text] [Related]
34. Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma.
Hau P; Ruemmele P; Kunz-Schughart LA; Doerfelt A; Hirschmann B; Lohmeier A; Koch H; Mueller A; Bogdahn U; Bosserhoff AK
Oncol Rep; 2004 Dec; 12(6):1355-64. PubMed ID: 15547763
[TBL] [Abstract][Full Text] [Related]
35. Expression, function and clinical relevance of MIA (melanoma inhibitory activity).
Bosserhoff AK; Buettner R
Histol Histopathol; 2002 Jan; 17(1):289-300. PubMed ID: 11813878
[TBL] [Abstract][Full Text] [Related]
36. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression.
Bosserhoff AK
Pigment Cell Res; 2005 Dec; 18(6):411-6. PubMed ID: 16280006
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
38. Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.
Yip KT; Zhong X; Seibel N; Arnolds O; Schöpel M; Stoll R
Biointerphases; 2017 May; 12(2):02D415. PubMed ID: 28565914
[TBL] [Abstract][Full Text] [Related]
39. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
40. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
